Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathoph...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2018-09, Vol.9 (70), p.33416-33439
Hauptverfasser:	Singer, Jack W, Fleischman, Angela, Al-Fayoumi, Suliman, Mascarenhas, John O, Yu, Qiang, Agarwal, Anupriya
Format:	Artikel
Sprache:	eng
Schlagworte:	Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	33439
container_issue	70
container_start_page	33416
container_title	Oncotarget
container_volume	9
creator	Singer, Jack W Fleischman, Angela Al-Fayoumi, Suliman Mascarenhas, John O Yu, Qiang Agarwal, Anupriya
description	Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.
doi_str_mv	10.18632/oncotarget.26058
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6161786</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2116120847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3808-c56f2fdc8c245ca2168292f225d2d97f3f1efbf0c885a4c6eee3d921065794e33</originalsourceid><addsrcrecordid>eNpVUU1LAzEQDaJYqf4AL5JjPazmY7ObvQgifhQLgujFS0izkza63dQkK_jvDX7WuczAe2_mMQ-hQ0pOqKw4O_W98UmHBaQTVhEht9AebcqmYELw7Y15hA5ifCa5RFlL1uyiESesbpqa7qGnab90c5ec77G32PUJQgfDi-sLigMYWCcfCh2jN04naHFGdARM8WR6f35Lj7GOWOO0hKDXMCRncEwhMxfv-2jH6i7CwXcfo8ery4eLm2J2dz29OJ8VhksiCyMqy2xrpGGlMJrRKntkljHRsrapLbcU7NwSI6XQpakAgLcNo6QSdVMC52N09rV3PcxX0Bros4FOrYNb6fCuvHbqP9K7pVr4N1XRitb5lWM0-V4Q_OsAMamViwa6Tvfgh6gYzURGZFlnKv2imuBjDGB_z1CiPmNRf7Goz1iy5mjT36_iJwT-Ab38jHc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2116120847</pqid></control><display><type>article</type><title>Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Singer, Jack W ; Fleischman, Angela ; Al-Fayoumi, Suliman ; Mascarenhas, John O ; Yu, Qiang ; Agarwal, Anupriya</creator><creatorcontrib>Singer, Jack W ; Fleischman, Angela ; Al-Fayoumi, Suliman ; Mascarenhas, John O ; Yu, Qiang ; Agarwal, Anupriya</creatorcontrib><description>Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.26058</identifier><identifier>PMID: 30279971</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Review</subject><ispartof>Oncotarget, 2018-09, Vol.9 (70), p.33416-33439</ispartof><rights>Copyright: © 2018 Singer et al. 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3808-c56f2fdc8c245ca2168292f225d2d97f3f1efbf0c885a4c6eee3d921065794e33</citedby><cites>FETCH-LOGICAL-c3808-c56f2fdc8c245ca2168292f225d2d97f3f1efbf0c885a4c6eee3d921065794e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161786/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161786/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30279971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singer, Jack W</creatorcontrib><creatorcontrib>Fleischman, Angela</creatorcontrib><creatorcontrib>Al-Fayoumi, Suliman</creatorcontrib><creatorcontrib>Mascarenhas, John O</creatorcontrib><creatorcontrib>Yu, Qiang</creatorcontrib><creatorcontrib>Agarwal, Anupriya</creatorcontrib><title>Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.</description><subject>Review</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LAzEQDaJYqf4AL5JjPazmY7ObvQgifhQLgujFS0izkza63dQkK_jvDX7WuczAe2_mMQ-hQ0pOqKw4O_W98UmHBaQTVhEht9AebcqmYELw7Y15hA5ifCa5RFlL1uyiESesbpqa7qGnab90c5ec77G32PUJQgfDi-sLigMYWCcfCh2jN04naHFGdARM8WR6f35Lj7GOWOO0hKDXMCRncEwhMxfv-2jH6i7CwXcfo8ery4eLm2J2dz29OJ8VhksiCyMqy2xrpGGlMJrRKntkljHRsrapLbcU7NwSI6XQpakAgLcNo6QSdVMC52N09rV3PcxX0Bros4FOrYNb6fCuvHbqP9K7pVr4N1XRitb5lWM0-V4Q_OsAMamViwa6Tvfgh6gYzURGZFlnKv2imuBjDGB_z1CiPmNRf7Goz1iy5mjT36_iJwT-Ab38jHc</recordid><startdate>20180907</startdate><enddate>20180907</enddate><creator>Singer, Jack W</creator><creator>Fleischman, Angela</creator><creator>Al-Fayoumi, Suliman</creator><creator>Mascarenhas, John O</creator><creator>Yu, Qiang</creator><creator>Agarwal, Anupriya</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180907</creationdate><title>Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy</title><author>Singer, Jack W ; Fleischman, Angela ; Al-Fayoumi, Suliman ; Mascarenhas, John O ; Yu, Qiang ; Agarwal, Anupriya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3808-c56f2fdc8c245ca2168292f225d2d97f3f1efbf0c885a4c6eee3d921065794e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Singer, Jack W</creatorcontrib><creatorcontrib>Fleischman, Angela</creatorcontrib><creatorcontrib>Al-Fayoumi, Suliman</creatorcontrib><creatorcontrib>Mascarenhas, John O</creatorcontrib><creatorcontrib>Yu, Qiang</creatorcontrib><creatorcontrib>Agarwal, Anupriya</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singer, Jack W</au><au>Fleischman, Angela</au><au>Al-Fayoumi, Suliman</au><au>Mascarenhas, John O</au><au>Yu, Qiang</au><au>Agarwal, Anupriya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2018-09-07</date><risdate>2018</risdate><volume>9</volume><issue>70</issue><spage>33416</spage><epage>33439</epage><pages>33416-33439</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>30279971</pmid><doi>10.18632/oncotarget.26058</doi><tpages>24</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1949-2553
ispartof	Oncotarget, 2018-09, Vol.9 (70), p.33416-33439
issn	1949-2553 1949-2553
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6161786
source	PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals
subjects	Review
title	Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T21%3A55%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20interleukin-1%20receptor-associated%20kinase%201%20(IRAK1)%20as%20a%20therapeutic%20strategy&rft.jtitle=Oncotarget&rft.au=Singer,%20Jack%20W&rft.date=2018-09-07&rft.volume=9&rft.issue=70&rft.spage=33416&rft.epage=33439&rft.pages=33416-33439&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.26058&rft_dat=%3Cproquest_pubme%3E2116120847%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2116120847&rft_id=info:pmid/30279971&rfr_iscdi=true